The OTC heartburn drugs market is projected to grow from USD 30,316.1 million in 2026 to USD 48,913.4 million by 2036, at a CAGR of 4.9%. Proton pump inhibitors will dominate with a 41.0% market share, while occasional heartburn will lead the applications segment with a 54.0% share.